Skip to main content

Ascendis Pharma AS (ASND) Stock

Ascendis Pharma AS Stock Details, Movements and Public Alerts

Stock Details

Ascendis Pharma AS (ASND), a prominent company in the healthcare sector within the biotechnology industry, is based in USA and primarily trades on the NASDAQ.Currently, the stock is trading at $202.99. Over the past 52 weeks, it has ranged between $118.03 and $229.94. This places the current price at 88.3% of its 52-week high and 72.0% above its 52-week low. Recent trading volume was recorded at 894,165. The 14-day Relative Strength Index (RSI) stands at 44.29, suggesting neutral conditions. The stock is currently trading below its 50-day moving average of $207.04 by 1.96%. Similarly, it is above its 200-day moving average of $185.71 by 9.30%. The MACD histogram is -0.50, indicating bearish momentum (MACD Line: 0.58, Signal Line: 1.08).

52-Week Range

$229.94 - $118.03

-11.72% from high · +71.98% from low

Avg Daily Volume

672,776

20-day average

100-day avg: 526,605

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

N/A

Forward P/E

47.62

Price to Book

14.55

EV/EBITDA

-20.75

EPS (TTM)

-$4.47

Price to Sales

19.18

Beta

0.45

Less volatile than market

Q:How is ASND valued relative to its earnings and growth?
Valuation data is not available for this stock.
Q:What is ASND's risk profile compared to the market?
With a beta of 0.45, Ascendis Pharma AS is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 14.55 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

-36.00%

Operating Margin

5.15%

EBITDA

$-133,708,000

Return on Equity

-818.00%

Return on Assets

-7.69%

Revenue Growth (YoY)

269.40%

Earnings Growth (YoY)

0.00%

Q:How profitable and efficient is ASND's business model?
Ascendis Pharma AS achieves a profit margin of -36.00%, meaning it retains $-36.00 from every $100 in revenue after all expenses. This relatively low margin suggests the company operates in a competitive environment or high-cost industry where profitability is challenging. The operating margin of 5.15% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at -818.00% and ROA at -7.69%, the company achieves moderate returns on invested capital.
Q:What are ASND's recent growth trends?
Ascendis Pharma AS's revenue grew by 269.40% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends.0 These growth metrics should be evaluated against BIOTECHNOLOGY industry averages for proper context.

Company Size & Market

Market Cap

$12.4B

Revenue (TTM)

$646.55M

Revenue/Share (TTM)

$10.73

Shares Outstanding

61.10M

Book Value/Share

-$3.32

Asset Type

Common Stock

Q:What is ASND's market capitalization and position?
Ascendis Pharma AS has a market capitalization of $12.4B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 61.10M shares outstanding, the company's ownership is relatively concentrated. As a participant in the BIOTECHNOLOGY industry, it competes with other firms in this sector.
Q:How does ASND's price compare to its book value?
Ascendis Pharma AS's book value per share is -$3.32, while the current stock price is $202.99, resulting in a price-to-book (P/B) ratio of -61.12. Trading below book value can indicate the market perceives challenges ahead, or it might represent a value opportunity if the assets are quality and earnings can recover. Value investors often screen for P/B ratios below 1.0. As a common stock, this represents equity ownership with voting rights.

Analyst Ratings

Analyst Target Price

$260.32

28.24% upside potential

Analyst Recommendations

Strong Buy

2

Buy

13

Hold

0

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for ASND?
15 analysts cover ASND with 100% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $260.32 implies 28.2% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ASND?
Current analyst recommendations:2 Strong Buy, 13 Buy, 000The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jan 11, 2026, 02:04 AM

Technical Indicators

RSI (14-day)

44.29

Neutral

50-Day Moving Average

$207.04

-1.96% below MA-50

200-Day Moving Average

$185.71

9.30% above MA-200

MACD Line

0.58

MACD Signal

1.08

MACD Histogram

-0.50

Bearish

Q:What does ASND's RSI value tell investors?
The RSI (Relative Strength Index) for ASND is currently 44.29, indicating the stock is in neutral territory (40-60 range). Neither buyers nor sellers have clear control, suggesting consolidation or balanced market forces. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret ASND's MACD and moving average crossovers?
MACD analysis shows the MACD line at 0.58 below the signal line at 1.08, with histogram at -0.50. This bearish crossover indicates downward pressure. The 50-day MA ($207.04) is above the 200-day MA ($185.71), forming a golden cross pattern that typically signals a long-term uptrend. Price is currently between the MAs, suggesting transition.

Indicators last updated: Jan 11, 2026, 12:35 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for ASND and get notified when the price changes.

Stay Ahead of the Market with Ascendis Pharma AS Alerts

Set up price alerts for Ascendis Pharma AS and get notified instantly when the price hits your target. Never miss an important price movement again.